$1.09
+0.05 (+4.81%)
Open$1.02
Previous Close$1.04
Day High$1.10
Day Low$1.01
52W High$2.35
52W Low$0.61
Volume—
Avg Volume119.2K
Market Cap17.21M
P/E Ratio—
EPS$-2.31
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,889.0% upside
Current
$1.09
$1.09
Target
$32.58
$32.58
$17.80
$32.58 avg
$40.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.37B | 2.19M | 1.96M |
| Net Income | -1,905,604,623 | -647,190 | -493,473 |
| Profit Margin | -11,927.5% | -29.6% | -25.2% |
| EBITDA | -2,736,795,749 | -712,204 | -583,546 |
| Free Cash Flow | — | -781,686 | -525,232 |
| Rev Growth | — | +18.0% | +10.8% |
| Debt/Equity | 0.11 | 0.28 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |